Canada's Xenon Pharmaceuticals, a drug discovery and development company, has appointed Charles J. Cohen as vice president of discovery research.
Cohen brings broad and diverse expertise which will be applicable to our multiple discovery and pre-clinical programmes. He has spent about 25 years in the pharmaceutical/biotechnology industry with positions at Bayer Pharmaceuticals, Merck & Co and Vertex Pharmaceuticals. He held senior scientific positions and has published widely in the area of pain and more broadly in cellular neuroscience and neurology.
"Charlie brings a unique combination of drug discovery experience and leadership including in areas that are highly relevant to Xenon such as pain," said Xenon's president and ceo Simon Pimstone. "With a drug candidate for pain currently in clinical trials, and a backup compound expected to follow, we are certain that Charlie's background will be of great benefit to Xenon."